Back

Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trial

30 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Panayiotis Iliakis

Hippokration General Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Baseline characteristics and antihypertensive patterns in Finnish patients with hypertension and kidney disease
Professor T. Niiranen (Turku, FI)
Abstract Slides
Presentation thumbnail
Artificial intelligence-assisted personalised dose titration for hypertension: safety and feasibility results of the CURATE.AI pilot randomised controlled trial
Doctor X. Tadeo (Singapore, SG)
Abstract Slides
Presentation thumbnail
Predicting individual blood pressure response to additional antihypertensive treatment: a prototype decision support tool for healthcare professionals in the community
Associate Professor A. Gupta (London, GB)
Abstract Slides
Presentation thumbnail
Digital AI lifestyle support improves blood pressure control on top of standard dual antihypertensive therapy
Mr B. Rozibaev (Tashkent, UZ)
Abstract Slides
Presentation thumbnail
Modifiable risk factors and 5-year and lifetime risks of cardiovascular disease among 0.5 million hypertensive patients in primary care
Doctor J. Wang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Pharmacotherapy in hypertension

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of hyperkalaemia and worsening renal function on pharmacotherapy in hospitalized patients with heart failure
20 May 2023
thumbnail
Congress Presentation
A safety and pharmacodynamic study of the highly selective aldosterone synthase inhibitor PB6440 in the cynomolgus monkey
26 August 2022
thumbnail
Congress Presentation
Eplerenone versus spironolactone and outcomes in patients with heart failure: a nationwide cohort study
21 May 2022
thumbnail
Congress Presentation
Renal function and intensive blood pressure lowering in high-risk adults without diabetes: insights from the Systolic Blood Pressure Intervention Trial (SPRINT)
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources